Physician profile
Andrea Degendice
NPI 1609951490
$495.07
in general payments reported to CMS, 2019-2025
5 companies · $13.99 in 2025
The $13.99 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $202 · 2023: $49.36 · 2024: $16.45 · 2025: $13.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $253.18 | 2021-2023 | |
| Galderma Laboratories, L.P. | $169.03 | 2021-2025 | |
| Virtus Pharmaceuticals LLC | $25.89 | 2022 | |
| Novo Nordisk INC | $25.21 | 2021 | |
| Lilly USA, LLC | $21.76 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Degendice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.